Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The new facility is expected to generate 500-600 new jobs in the region
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
